Litcius/Paper detail

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer

Tizita Zeleke, Qingfei Pan, Codruța Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony A. High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva

2022Nature Cancer77 citationsDOIOpen Access PDF

Topics & Concepts

Breast cancerMedicineInternal medicineOncologyPsychologyCancerCancer researchHistone Deacetylase Inhibitors ResearchPeptidase Inhibition and AnalysisProtein Degradation and Inhibitors
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer | Litcius